Michał Kliszczak

PCR.smart™ is a compact platform for molecular diagnostics in qPCR, PCR, LAMP. The device performs isolation, amplification, detection and interpretation of sample results (any biological material containing DNA) in a few simple steps. All this in an extremely compact casing and using patented technology, guaranteeing results in up to 90 minutes, taking into account the entire process from sample preparation, through isolation, amplification and result interpretation. Areas of application: food safety, veterinary, water testing, modern agriculture, technological prevention for insurance market.

Green Lanes powstało z myślą o innowacyjnym i ekologicznym podejściu do tworzenia produktów i rozwijania technologii, a także nowym sposobie myślenia o konopiach włóknistych. Dzięki inwestycjom oraz zapleczu ekspertów, których cechuje zamiłowanie do konopi i doświadczenie z różnych dziedzin nauki i biznesu, Green Lanes stawia sobie za cel zrewolucjonizowanie rynku konopnego w Polsce i Europie. Prowadzimy badania w zakresie wykorzystania każdego elementu konopi włóknistych od korzenia, przez łodygę, po ziarno i kwiaty. Analizujemy możliwe zastosowania zarówno pod kątem właściwości konopi, stosowanych technologii, jak i wielkości rynku i potrzeby znalezienia bardziej ekologicznych alternatyw dla istniejących rozwiązań w danej branży.Wybrane projekty wprowadzamy w życie tworząc spółki, których celem jest realizacja zidentyfikowanej szansy. Rozwijamy je w oparciu o nasze doświadczenie w branży oraz zdolność do pozyskiwania partnerów branżowych i kapitału niezbędnego do realizacji kolejnych kamieni milowych.

Genomtec is a MedTech company specializing in the development of advanced technologies in the field of genetic diagnostics. The companys flagship project is the Genomtec ID mobile diagnostic system, which allows for fast and precise molecular analysis outside the laboratory environment without the need to involve qualified laboratory personnel. The company has EU CE-IVD certification for the Genomtec ID RP5-PLEX diagnostic panel, which simultaneously detects the presence of the most common respiratory tract infections. The solution uses microfluidic technology and proprietary patented SNAAT® isothermal technology. The Genomtec technology is protected by 11 patents, for example, in Europe, the USA, and Japan, with over 35 patent pending applications on global markets. Genomtecs second project in oncology, "OncoSNAAT," consists of developing technology and a new automated system for mutation detection in the field of clinical oncology. This is based on a lab-on-chip solution and isothermal nucleic acid amplification techniques. The companys registered office is located in Wroclaw, Poland. Genomtec also has a branch in the UK, where part of the international research and engineering team is located. Genomtec combines confidence in molecular diagnostics with radical simplicity and cost reduction. The Genomtec team is a unique combination of experienced individuals from various fields with a common passion for creation. We work with a group of young, ambitious scientists and constructors. Everyday, we rely on our outstanding experienced scientists as well as our experts on commercialization and building and enforcing effective market strategies.

Intelliseq is a genomics company turning complex DNA data into clear, actionable insights. Our bespoke pipelines allow for modular bioinformatics workflows to make next-generation sequencing (NGS) interpretation fast, scalable, and clinically relevant - empowering diagnostic labs, biopharma, and research institutions to accelerate precision medicine. By delivering user-friendly, automated pipelines that ensure reproducibility and regulatory readiness, Intelliseq bridges the gap between complex genomics and practical healthcare solutions - without the need for in-house bioinformatics expertise.

BIOTTS, a Polish-American biotech company, develops proprietary drugs in oncology, diabetology and pain utilizing unique formulations and drug delivery technologies. Biotts scientists have developed a breakthrough technology of universal transdermal therapeutic system MTC-Y (Multifunctional Transdermal Carrier-Y). The properties of the carrier increase the bioavailability of active substances several times, enabling them to penetrate through the skin into soft tissues and bones. The carrier can be easily modified to obtain targeted action in pathologically changed tissues. Thanks to the system, it is possible to reduce the therapeutic dose of the drug while maintaining its original effect and simultaneously reducing the side effects. In addition, the system enables the transport of one to several active substances, which makes it possible to design multi-component drugs.

APS has developed and commercialised a unique system for detecting and neutralising drones: SKYctrl. The system allows for a reliable operation night and day under any weather conditions, including clouds, fog and rain with an effective drone detection distance of up to 6000 m. It is perfectly suited to protect: a. critical infrastructure installations (airports, power plants, ports, etc.) b. government buildings and installations c. military installations d. VIPs e. borders f. private property g. events SKYctrl is based on the following sensors: 1. FIELDctrl 3D MIMO Radars - operating in the unlicensed 10 GHz band, affordable while delivering superior drone detection capabilities. Advanced signal processing algorithms minimize false alarm rates and enable to differentiate drones from birds. 2. EOIR sensors - a set of cameras allows identification of drones and recording incident footage for post-incident actions night and day. On the neutralization side, SKYctrl is equipped with proprietary soft-kill: multi-band jammers. Directive antennas of the jammers are cued on target automatically by FIELDctrl 3D MIMO radars. The system comes with a friendly to use software that provides for drones monitoring, incidents archiving, sms, email and system alerts. SKYctrl is easily scalable allowing cost-efficient implementation for both large and small areas/installations.

XTPL is paving the way in innovation, revolutionising industries with our groundbreaking additive technology solutions. Our journey began with rigorous research and development, and now were shaping the future with our technological expertise. Our innovative approach is evident in our patented Ultra-Dispensing System (UPD) and range of nanoinks and nanopastes, which offer unparalleled precision and efficiency in microelectronics applications. As a total supplier, we offer tailored end-to-end solutions that cater to our clients unique needs. From concept to final product, we provide the support, expertise, and innovative solutions that ensure success. We continuously evolve and expand our portfolio of patented solutions, showcasing our commitment to lead the microelectronics revolution. At XTPL, we dont just envision the future, we create it. XTPL. Powering the microelectronics of tomorrow.

PCR.smart™ is a compact platform for molecular diagnostics in qPCR, PCR, LAMP. The device performs isolation, amplification, detection and interpretation of sample results (any biological material containing DNA) in a few simple steps. All this in an extremely compact casing and using patented technology, guaranteeing results in up to 90 minutes, taking into account the entire process from sample preparation, through isolation, amplification and result interpretation. Areas of application: food safety, veterinary, water testing, modern agriculture, technological prevention for insurance market.

Green Lanes powstało z myślą o innowacyjnym i ekologicznym podejściu do tworzenia produktów i rozwijania technologii, a także nowym sposobie myślenia o konopiach włóknistych. Dzięki inwestycjom oraz zapleczu ekspertów, których cechuje zamiłowanie do konopi i doświadczenie z różnych dziedzin nauki i biznesu, Green Lanes stawia sobie za cel zrewolucjonizowanie rynku konopnego w Polsce i Europie. Prowadzimy badania w zakresie wykorzystania każdego elementu konopi włóknistych od korzenia, przez łodygę, po ziarno i kwiaty. Analizujemy możliwe zastosowania zarówno pod kątem właściwości konopi, stosowanych technologii, jak i wielkości rynku i potrzeby znalezienia bardziej ekologicznych alternatyw dla istniejących rozwiązań w danej branży.Wybrane projekty wprowadzamy w życie tworząc spółki, których celem jest realizacja zidentyfikowanej szansy. Rozwijamy je w oparciu o nasze doświadczenie w branży oraz zdolność do pozyskiwania partnerów branżowych i kapitału niezbędnego do realizacji kolejnych kamieni milowych.

Genomtec is a MedTech company specializing in the development of advanced technologies in the field of genetic diagnostics. The companys flagship project is the Genomtec ID mobile diagnostic system, which allows for fast and precise molecular analysis outside the laboratory environment without the need to involve qualified laboratory personnel. The company has EU CE-IVD certification for the Genomtec ID RP5-PLEX diagnostic panel, which simultaneously detects the presence of the most common respiratory tract infections. The solution uses microfluidic technology and proprietary patented SNAAT® isothermal technology. The Genomtec technology is protected by 11 patents, for example, in Europe, the USA, and Japan, with over 35 patent pending applications on global markets. Genomtecs second project in oncology, "OncoSNAAT," consists of developing technology and a new automated system for mutation detection in the field of clinical oncology. This is based on a lab-on-chip solution and isothermal nucleic acid amplification techniques. The companys registered office is located in Wroclaw, Poland. Genomtec also has a branch in the UK, where part of the international research and engineering team is located. Genomtec combines confidence in molecular diagnostics with radical simplicity and cost reduction. The Genomtec team is a unique combination of experienced individuals from various fields with a common passion for creation. We work with a group of young, ambitious scientists and constructors. Everyday, we rely on our outstanding experienced scientists as well as our experts on commercialization and building and enforcing effective market strategies.

Intelliseq is a genomics company turning complex DNA data into clear, actionable insights. Our bespoke pipelines allow for modular bioinformatics workflows to make next-generation sequencing (NGS) interpretation fast, scalable, and clinically relevant - empowering diagnostic labs, biopharma, and research institutions to accelerate precision medicine. By delivering user-friendly, automated pipelines that ensure reproducibility and regulatory readiness, Intelliseq bridges the gap between complex genomics and practical healthcare solutions - without the need for in-house bioinformatics expertise.

BIOTTS, a Polish-American biotech company, develops proprietary drugs in oncology, diabetology and pain utilizing unique formulations and drug delivery technologies. Biotts scientists have developed a breakthrough technology of universal transdermal therapeutic system MTC-Y (Multifunctional Transdermal Carrier-Y). The properties of the carrier increase the bioavailability of active substances several times, enabling them to penetrate through the skin into soft tissues and bones. The carrier can be easily modified to obtain targeted action in pathologically changed tissues. Thanks to the system, it is possible to reduce the therapeutic dose of the drug while maintaining its original effect and simultaneously reducing the side effects. In addition, the system enables the transport of one to several active substances, which makes it possible to design multi-component drugs.